ADC Therapeutics S.A.
HealthcareNYSE:ADCT · New York Stock Exchange
-$0.01 today
Vol 1.55M · Avg 1.61M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
76.7%
avg -33.1%
ROIC
-42.3%
avg -50.7%
ROA
-44.1%
avg -47.7%
Analysis
ROE is currently the strongest return metric at 76.7% versus its period average of -33.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ameet Mallik | Chief Executive Officer & Director | $1.41M | — | 53 | $1.55M | 1.22% |
Mohamed Zaki | Chief Medical Officer | $1.15M | — | 61 | $707,020.00 | 0.56% |
Jose I. Carmona | Chief Financial Officer | $860,603.00 | — | 54 | $760,256.00 | 0.60% |
David S. Ege | Chief Technical Officer | — | — | 52 | $0.00 | <0.01% |
Peter J. Graham | Secretary and Chief Legal & Compliance Officer | — | — | 59 | $653,834.00 | 0.51% |
Kimberly Pope | Senior Vice President & Chief People Officer | — | — | 59 | — | — |
Kristen Harrington-Smith | Chief Commercial Officer | — | — | 53 | — | — |
Lisa Michelle Kallebo | Corporate Controller & Chief Accounting Officer | — | — | — | $133,657.00 | 0.11% |
Marcy Graham | Investor Relations Officer | — | — | 59 | $653,834.00 | 0.51% |
Nicole Riley | Head of Investor Relations & Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$0.00
Sells
6
$19.64M
Net Sentiment
$19.64M
Net selling
Most Active
Redmile Group, LLC
7 transactions
Analysis
Insiders reported 1 buys worth $0.00 and 6 sells worth $19.64M over the last 12 months. That adds up to net selling of $19.64M. Redmile Group, LLC was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +209.9% | +28.7% (9yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +209.9% over three years. Forward estimates point to Revenue at +28.7% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.98B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Who manages ADCT?
ADC Therapeutics S.A. (ADCT) lists 10 active executives. The top listed executive is David S. Ege, Chief Technical Officer.
Are ADCT insiders buying or selling?
Recent insider activity shows net selling of $52.96M.
Explore More
Continue the stock analysis
Jump to another research area for this company.